Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Assets: 2022-2025

Historic Return on Assets for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -0.57%.

  • InMed Pharmaceuticals' Return on Assets rose 4.00% to -0.57% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.57%, marking a year-over-year increase of 4.00%. This contributed to the annual value of -0.60% for FY2025, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Return on Assets is -0.57%, which was up 13.59% from -0.66% recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Return on Assets peaked at -0.42% during Q1 2024, and registered a low of -1.40% during Q3 2022.
  • For the 3-year period, InMed Pharmaceuticals' Return on Assets averaged around -0.66%, with its median value being -0.61% (2024).
  • As far as peak fluctuations go, InMed Pharmaceuticals' Return on Assets spiked by 84bps in 2023, and later plummeted by 51bps in 2025.
  • Quarterly analysis of 4 years shows InMed Pharmaceuticals' Return on Assets stood at -1.08% in 2022, then skyrocketed by 59bps to -0.49% in 2023, then tumbled by 35bps to -0.83% in 2024, then grew by 4bps to -0.57% in 2025.
  • Its Return on Assets was -0.57% in Q3 2025, compared to -0.66% in Q2 2025 and -0.93% in Q1 2025.